JP2023553414A - ドライ型加齢黄斑変性症(amd)治療用組成物 - Google Patents

ドライ型加齢黄斑変性症(amd)治療用組成物 Download PDF

Info

Publication number
JP2023553414A
JP2023553414A JP2023534245A JP2023534245A JP2023553414A JP 2023553414 A JP2023553414 A JP 2023553414A JP 2023534245 A JP2023534245 A JP 2023534245A JP 2023534245 A JP2023534245 A JP 2023534245A JP 2023553414 A JP2023553414 A JP 2023553414A
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutically acceptable
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553414A5 (cg-RX-API-DMAC7.html
Inventor
カッジャーノ、アンソニー
カタラノ、スーザン
ハンビー、メアリー
イゾ、ニコラス
ルック、ゲイリー
リシュトン、ギルバート
Original Assignee
コグニション セラピューティクス インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コグニション セラピューティクス インク. filed Critical コグニション セラピューティクス インク.
Publication of JP2023553414A publication Critical patent/JP2023553414A/ja
Publication of JP2023553414A5 publication Critical patent/JP2023553414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023534245A 2020-12-11 2021-12-10 ドライ型加齢黄斑変性症(amd)治療用組成物 Pending JP2023553414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
US63/124,695 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (2)

Publication Number Publication Date
JP2023553414A true JP2023553414A (ja) 2023-12-21
JP2023553414A5 JP2023553414A5 (cg-RX-API-DMAC7.html) 2024-12-13

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534245A Pending JP2023553414A (ja) 2020-12-11 2021-12-10 ドライ型加齢黄斑変性症(amd)治療用組成物

Country Status (10)

Country Link
US (1) US20240009168A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553414A (cg-RX-API-DMAC7.html)
KR (1) KR20230118158A (cg-RX-API-DMAC7.html)
CN (1) CN116867488A (cg-RX-API-DMAC7.html)
AU (1) AU2021396380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200346A1 (cg-RX-API-DMAC7.html)
IL (1) IL303592A (cg-RX-API-DMAC7.html)
MX (1) MX2023006677A (cg-RX-API-DMAC7.html)
WO (1) WO2022125925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
ES2969373B2 (es) 2022-10-14 2025-02-06 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo
WO2025122753A2 (en) * 2023-12-08 2025-06-12 Cognition Therapeutics, Inc. Compositions and methods for the treatment of niemann-pick disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509932A (ja) * 2003-10-30 2007-04-19 セルジーン・コーポレーション 黄斑変性症の治療用サイトカイン阻害薬
JP2012506449A (ja) * 2008-10-22 2012-03-15 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
JP2017507122A (ja) * 2014-01-31 2017-03-16 コグニション セラピューティクス,インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509932A (ja) * 2003-10-30 2007-04-19 セルジーン・コーポレーション 黄斑変性症の治療用サイトカイン阻害薬
JP2012506449A (ja) * 2008-10-22 2012-03-15 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
JP2017507122A (ja) * 2014-01-31 2017-03-16 コグニション セラピューティクス,インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACS MED. CHEM. LETT., vol. 12, JPN6025046591, August 2021 (2021-08-01), pages 1389 - 1395, ISSN: 0005733106 *
AMYLOID-BETA OLIGOMER RECEPTOR INHIBITORS (CT1812), JPN6025046589, June 2019 (2019-06-01), ISSN: 0005733107 *
BIORXIV, JPN6025046590, July 2020 (2020-07-01), ISSN: 0005733108 *
J. MED. CHEM., vol. 51, JPN6025046592, 2008, pages 1546 - 1559, ISSN: 0005733105 *

Also Published As

Publication number Publication date
KR20230118158A (ko) 2023-08-10
AU2021396380A1 (en) 2023-06-22
CA3200346A1 (en) 2022-06-16
CN116867488A (zh) 2023-10-10
EP4259129A4 (en) 2024-11-27
IL303592A (en) 2023-08-01
WO2022125925A1 (en) 2022-06-16
MX2023006677A (es) 2023-06-27
US20240009168A1 (en) 2024-01-11
EP4259129A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US20240009168A1 (en) Compositions for treating dry age-related macular degeneration (amd)
TWI400080B (zh) 藥物於治療患有青光眼和其他退化性眼疾之人的視力喪失上之用途
US11981636B2 (en) Compositions for treating neurodegenerative diseases
EP3756665B1 (en) Interval therapy for the treatment of eye diseases
KR20230159546A (ko) 신경학적 질환을 치료하기 위한 조성물 및 방법
US9694010B2 (en) Therapeutic formulation and methods of treatment
US11707445B2 (en) Composition for blocking angiogenesis
JP7706376B2 (ja) 神経修復方法
RU2792562C2 (ru) Композиции для лечения нейродегенеративных заболеваний
WO2025122753A2 (en) Compositions and methods for the treatment of niemann-pick disease
KR20260049797A (ko) 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
CA3061787C (en) Compositions for treating neurodegenerative diseases
JP2017218384A (ja) 網膜疾患の予防または治療のための医薬組成物
US20200237715A1 (en) COX-2 Inhibitors for the Treatment of Ocular Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260518